Application of C. elegans cancer screening test for the detection of pancreatic tumor in genetically engineered mice
- PMID: 31534627
- PMCID: PMC6739214
- DOI: 10.18632/oncotarget.27124
Application of C. elegans cancer screening test for the detection of pancreatic tumor in genetically engineered mice
Abstract
Pancreatic ductal adenocarcinoma (PDAC) exhibits a very early onset of metastasis. Thus, early detection and treatment are pivotal to successful eradication of pancreatic cancers. Economical and non-invasive cancer screening systems is indispensable for this purpose. Previously our group developed a novel method to detect various kinds of human cancer using nematode Caenorhabditis elegans (C. elegans) that respond to cancer odor in urine; however, whether this method is useful for non-human species remains to be understood. In this study, we examined its effectiveness in the detection of murine pancreatic tumor spontaneously generated in genetically-engineered mice. We generated pancreas-specific Kras G12D and/or c-Met deletion mutant mice and measured the probability of spontaneous tumor generation in these mice. The chemotactic indexes of C. elegans to the urine samples of these mutant mice were measured. As previously described, oncogenic KrasG12D was necessary to induce pancreatic intraepithelial neoplasia in this mouse model, while c-Met mutation did not show further effect. The chemotactic analysis indicated that C. elegans avoids urine of healthy recipient mice, while they tended to be attracted to urine of mice with KrasG12D . Our study demonstrated that C. elegans can recognize the odor of pancreatic cancer in urine of KrasG12D model mouse, suggesting the similarity of cancer odor between species. Our result facilitates further studies on mechanism of cancer detection by C. elegans.
Keywords: C. elegans; early detection; genetically-engineered mice; pancreatic cancer.
Conflict of interest statement
CONFLICTS OF INTEREST Institutional endowments were received from Taiho Pharmaceutical Co., Ltd (Tokyo, Japan) [to Dr. H. Ishii], Evidence Based Medical Research Center INC. (Osaka, Japan) [to Dr. H. Ishii], UNITECH Co., Ltd. (Chiba, Japan) [to Dr. H. Ishii], IDEA Consultants, Inc. (Tokyo, Japan) [to Dr. H. Ishii], Kinshu-kai Medical Corporation (Osaka, Japan) [to Dr. H. Ishii], Chugai Co., Ltd. (London, UK) [to Dr. T. Satoh], Yakult Honsha Co., Ltd. [to Dr. T. Satoh], Ono Pharmaceutical Co., Ltd. (Osaka, Japan) [to Dr. T. Satoh], and Merck & Co., Ltd. (Whitehouse Station, NJ, USA) [to Dr. T. Satoh]; those sponsors had no role in the design or performance of the study, data collection, data management and interpretation, preparation of this article, or approval of the article. Drs. S. Kaifuchi and T. Hirotsu is employees of Hirotsu Bioscience Co., Ltd. (Tokyo, Japan).
Figures
Similar articles
-
A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.J Pathol. 2014 Oct;234(2):228-38. doi: 10.1002/path.4402. Epub 2014 Aug 4. J Pathol. 2014. PMID: 25042889
-
Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.Gastroenterology. 2015 Jun;148(7):1452-65. doi: 10.1053/j.gastro.2015.02.009. Epub 2015 Feb 13. Gastroenterology. 2015. PMID: 25683115
-
Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia.Cancer Res. 2007 Sep 1;67(17):8121-30. doi: 10.1158/0008-5472.CAN-06-4167. Cancer Res. 2007. PMID: 17804724
-
[Development of an Early Cancer Detection Method Using the Olfaction of the Nematode Caenorhabditis elegans].Yakugaku Zasshi. 2019;139(5):759-765. doi: 10.1248/yakushi.18-00185-4. Yakugaku Zasshi. 2019. PMID: 31061346 Review. Japanese.
-
Mutant KRAS in the initiation of pancreatic cancer.Biochim Biophys Acta. 2005 Nov 25;1756(2):97-101. doi: 10.1016/j.bbcan.2005.08.003. Epub 2005 Sep 7. Biochim Biophys Acta. 2005. PMID: 16169155 Review.
Cited by
-
State-of-the-Art Technology of Model Organisms for Current Human Medicine.Diagnostics (Basel). 2020 Jun 10;10(6):392. doi: 10.3390/diagnostics10060392. Diagnostics (Basel). 2020. PMID: 32532032 Free PMC article. Review.
-
Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion.Oncogene. 2020 Aug;39(34):5690-5707. doi: 10.1038/s41388-020-1381-6. Epub 2020 Jul 21. Oncogene. 2020. PMID: 32694611
-
Nematode-Applied Technology for Human Tumor Microenvironment Research and Development.Curr Issues Mol Biol. 2022 Feb 21;44(2):988-997. doi: 10.3390/cimb44020065. Curr Issues Mol Biol. 2022. PMID: 35723350 Free PMC article. Review.
-
Scent test using Caenorhabditis elegans to screen for early-stage pancreatic cancer.Oncotarget. 2021 Aug 17;12(17):1687-1696. doi: 10.18632/oncotarget.28035. eCollection 2021 Aug 17. Oncotarget. 2021. PMID: 34434497 Free PMC article.
-
C. elegans as a Powerful Tool for Cancer Screening.Biomedicines. 2022 Sep 23;10(10):2371. doi: 10.3390/biomedicines10102371. Biomedicines. 2022. PMID: 36289633 Free PMC article. Review.
References
-
- Tomihara H, Eguchi H, Yamada D, Gotoh K, Kawamoto K, Wada H, Asaoka T, Noda T, Takeda Y, Tanemura M, Mori M, Doki Y. Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma. Surg Today. 2017; 47:218–26. 10.1007/s00595-016-1405-6. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous